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Background: In patients with recurrent or second primary ipsilateral breast cancer, axillary staging is the key factor
in locoregional control and a strong prognostic characteristic. The efficient evaluation of lymphatic drainage of
re-sentinel lymph node biopsies (re-SLNBs) has remained a challenge in the management of ipsilateral primary or
recurrent breast cancer patients who are clinically lymph node negative. This study explores whether a SLNB for
patients with primary or recurrent breast cancer is possible after previous axillary surgery. It evaluates potential
reasons for mapping failure that might be associated with patients in this group.
Methods: Between March 2006 and November 2013, 458 patients were subjected to a breast SLNB. A
lymphoscintigraphy procedure was performed on 330 patients for sentinel lymph node (SLN) mapping on the day
of surgery. Seven patients with either a second primary cancer in the same breast or recurrent breast cancer were
described. Two of these seven patients had axillary lymph node dissection (ALND) during previous treatments and
five had SLNB. A dual mapping method was used for all patients. Preoperative lymphoscintigraphy was performed
four hours before surgery.
Results: SLNs were successfully remapped in six of seven (85.7%) patients, of whom five (71.43%) had previously
undergone SLNB and two (28.57%) previous ALND. Localizations of SLNs were ipsilateral axillary in three patients,
ipsilateral internal mammary in one patient, and contralateral axillary in two patients. An altered distribution of
lymph nodes was discovered in both patients with previous ALND. In one of the two patients, metastases were
found in an aberrant lymph drainage basin at the location of a non-ipsilateral axillary node (contralateral axillary
SLN). The second previously ALND patient had an internal mammary SLN. In one patient, mapping was unsuccessful
and the SLN was not identified.
Conclusions: Altered lymphatic drainage incidence increases following breast-conserving surgery for an initial
breast cancer, and the location of SLNs becomes unpredictable at the time of a second primary or recurrent
ipsilateral breast cancer. This leads to the necessity of using a radionuclide (lymphoscintigraphy) for a successful
re-mapping procedure. A re-SLNB is precise and beneficial even though there are few patients. A lymphoscintigraphy
can identify SLNs at their new unpredicted location.* Correspondence: handantokmak@gmail.com
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Table 1 Characteristics of patients on whom SLN
scintigraphy procedures were performed
Characteristics of patients Percentage (%)
Number of patients 330
Age of initial cancer diagnosis (years) 47.88
Median age (range) 48
Tumor size (mean size range) (mm) 18
Histology
Invasive ductal cancer 250 75.7
Invasive lobular cancer 56 16.9
Others 24 7.2
Stage
Stage I 145 43.9
Stage II 148 44.8
Stage III 37 11.2




Hormone receptor negative (ER-, PR-) 79 24.80
Triple negative (ER-, PR-, HER2-) 53 16
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In the management of breast cancer, a sentinel lymph
node biopsy (SLNB) has become standard care for staging
axilla in breast cancer patients with clinically negative axil-
lary lymph nodes [1]. The SLNB technique is a highly se-
lective approach based on the finding that tumor cells
migrating from a primary tumor metastasize to one or a
few lymph nodes before involving other lymph nodes.
It has been proven that prediction of the status of surviv-
ing regional nodes can be accurately carried out from the
results for sentinel lymph nodes (SLNs) [2,3]. It has been
stated that the local breast cancer recurrence rate is up to
5 to 10% for patients who are having breast-conserving
surgery [4,5]. In addition, new primary breast cancer con-
nected to earlier occurrences of SLNB or previous axillary
operations may be detected within the follow-up period [6].
The incidence of second primary ipsilateral or recurrent
breast cancer is progressively increasing in patients with
previously treated breast cancer, as would be expected.
Due to the cumulative adoption of breast-conserving sur-
gery, improved prognosis and gains in life expectancy for
patients with an initial early-stage breast cancer, this clin-
ical issue may become more common [6-10].
Methods
Between March 2006 and December 2013, a cohort of 458
consecutive patients with breast cancer proven by a biopsy
underwent SLNB (only blue dye, blue dye plus lymphos-
cintigraphy, and only lymphoscintigraphy) (Figure 1). On
the day of surgery, one-day lymphoscintigraphy (with or
without blue dye) was performed for 330 patients (Table 1).
A hand-held gamma probe (Navigator GPS, RMD Instru-
ments, England, UK) was used to explore the SLN in the
operation. A total of seven patients with a second primary
cancer in the same breast or recurrent breast cancer wereFigure 1 SLN scintigraphy procedures performed and patient distribu
lymphoscintigraphy; P, patients; SLN, sentinel lymph node; SLNB, sentinel lydescribed in this group. Among these seven patients who
already had undergone axillary procedures, two out of
seven patients had axillary lymph node dissection (ALND),
and five out of seven had SLNB.
Sentinel lymph node biopsy technique
SLN scintigraphy procedures were performed by a nu-
clear medicine physician using a standard technique. All
patients underwent preoperative lymphoscintigraphy on
the day of surgery. A combined periareolar intradermaltion. ALND, axillary lymph node dissection; Ca, cancer; lymphoscint,
mph node biopsy. Met+: Metastases positive.
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technique was used for all patients. After an injection of
800 to 1,000 μCi of filtered technetium sulfur colloid,
dynamic and static planar images were obtained. A hand-
held gamma probe (Navigator GPS) was used for identify-
ing the SLN and to determine if there was any non-SLN.
Isosulfan blue (5 mL) was injected just before the operation
for 70% of all patients to detect SLN in this study. All SLNs
and non-SLNs were evaluated intra-operatively by touch
preparation cytology. Axillary dissection was performed if
there were metastases and were identified in the SLN
either intra-operatively or through permanent cytology
evaluation. Regardless of SLN size, all dissected SLNs were
sectioned into 2-mm thicknesses (as closely as possible). If
the SLN was visually positive, less sectioning was per-
formed (and sometimes only one section was performed).
All dissected lymph nodes were evaluated through per-
manent cytology using hematoxylin and eosin staining and
immunohistochemistry. Micro-metastases were defined as
metastases ranging from 0.2 to 2 mm in size. Metastases
larger than 2 mm were identified as macro-metastases.
ALND was performed for the patients whose SLNB path-
ology results were positive. The results of the pathology
were compared and evaluated with the nodes in the in-
ternal mammary areas and in axillary areas, including the
contralateral axillary areas.
Results
All patients underwent an SLNB for both their first and
second axillary evaluations. SLNs were successfully re-
mapped for six out of seven (85.7%) patients. A mean of
1.4 (range 1 to 3) lymph nodes were determined through
lymphatic re-mapping for six out of seven patients.
Three patients (out of seven, 42.8%) showed alternative
lymphatic pathways; one of the three had an ipsilateral
internal mammary node and the other two had crossed
lymphatics to a contralateral axillary node. According to
an actual meta-analysis of the literature (by Maaskant-
Braat et al.) [7], which includes all studies on repeat
sentinel node biopsy in patients with locally recurrent
breast cancer, aberrant drainage pathways were visual-
ized (43.2%).
One of the six successfully remapped patients had a
contralateral axillary SLN, which proved to be micro-
metastatic (0.3 mm in permanent pathology) (16%) and
a confirmation contralateral ALND in this patient iden-
tified no additional positive axillary lymph nodes. This
patient had a previous ALND (46 months previous). A
pathologic examination of the internal mammary senti-
nel node was negative for metastases. The SLN could
not be found in one patient. A complete ALND was per-
formed in this patient. None of the dissected 11 lymph
nodes from this patient were positive for metastases
(false negative rate 0%).The aforementioned patient underwent primary lymph-
atic mapping and then a lumpectomy, following by ra-
diation therapy. It could be speculated that secondary
inflammatory changes associated with primary radiation
therapy decrease the feasibility of re-operative SLNB. In
the systematic review and meta-analysis of the literature by
Maaskant-Braat et al., sentinel node identification was suc-
cessful in 452 of 692 patients (65.3%). The identification
rate was significantly lower in patients who had undergone
a previous ALND (52.2%) (P < 0.0001) compared to pa-
tients who had undergone a previous SLNB (81%) [7].
The lymphoscintigraphy procedure was performed for
330 patients for SLN mapping, and these characteristics
are described in Table 1. There are other sub-classifications
of breast cancer as well, such as the one that classifies
breast cancers into luminal A, luminal B, basal and HER2
enriched [11]. Irrespective of the underlying breast cancer
subtype, the presence of axillary lymph node metastases is
associated with considerable poor disease-free as well as
overall survival [12,13]. Lymph node metastases remain a
very important prognostic variable, and identification of
lymph node metastases can potentially help in early
intervention by reducing the chances of breast cancer
progression.
At a 27-month mean follow-up after the second SLNB,
there were no axillary or other alternative lymph node
area recurrences. There was an 85.7% success rate in pa-
tients with new or recurrent cancer in the breast who
had both a previous SLNB and remapped SLNs. This is
a similar success rate as the primary SLNB. In this study,
re-operative SLNB failed in one out of seven patients
(14.2%) (Table 2).
Discussion
Reconstitution of alternative routes of drainage from the
lymph nodes may lead to the undesired result of additional
and previously unaffected nodes receiving primary drain-
age from the vicinity of the cancer-infected breast. Unpre-
dicted alternative lymphatic pathways might be prompted
by radiotherapy or previous operations could lead to dam-
age to the usual draining lymphatics [14-16]. The high
identification rate of altered lymphatic drainage in our
series is attributed to previous ALND and radiotherapy
(one of seven patients had ALND plus radiotherapy, one
patient ALND and one patient axillary radiotherapy).
There is clearly a necessity to conduct a second lymphatic
mapping injection and lymphoscintigraphy before SLNB.
Even patients with a virgin axilla will not have easy-to-
predict patterns of drainage, and there is a greater pos-
sibility of locating nodes outside the ipsilateral axilla
among patients who have underwent a previous axillary
operation [17-21].
Haagensen et al. hypothesized that, by permeating the
deep lymphatic plexus of the wall of the chest, tumor
Table 2 Characteristics of patients for whom re-SLN
scintigraphy procedures were performed
Characteristics of patients Number
Number of patients 7
Age initial cancer diagnosis (years) 52.1
Median age (range ) 49
Histology
Invasive ductal cancer 4
Invasive lobular cancer + invasive ductal 1
Invasive lobular cancer 1





Sentinel lymph node re-mapping results
Axillary region lymph nodes 3
Other than axillary region 2
Previous surgery
Breast-conserving surgery + ALND 2
Breast-conserving surgery + SLND 5
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the present study, two out of 330 (0.6%) consecutive pa-
tients were identified with contralateral axillary drainage
on lymphoscintigraphy. A contralateral SLN biopsy was
attempted in both patients; only one of the two patients
who had a contralateral axillary SLN proved to be positive
for a tumor. The second patient also had an ipsilateral
SLN, and both ipsilateral and contralateral SLNBs showed
no metastatic involvement. There has been no ipsilateral
or contralateral axillary recurrence (mean 54 months) fol-
lowing a negative SLNB in these patients. Contralateral
axillary lymph node metastases are generally associated
with the aggressiveness of the primary tumor’s pathology.
Morcos et al. Compared data for 401 breast cancer pa-
tients who did not have contralateral axillary lymph node
metastases with that of 21 patients with contralateral axil-
lary lymph node metastases. Their retrospective analysis
showed that tumor grade, lymphovascular invasion, tumor
size, hormone receptor negativity and HER2 overexpres-
sion increases the risk of contralateral axillary metastases
[23]. In our series, the patient with contralateral metasta-
ses had grade 2 invasive ductal carcinoma, T2, ER-PR re-
ceptor positive, and HER2 negative. As seen in our series,
the histopathological features of the tumor in this patient
with contralateral axillary metastasis were not aggressive.
In comparison, the findings for this patient drive attention
to the range of different etiologies that might have caused
contralateral axillary drainage and altered the metastases
area. Contralateral axillary metastases have been regardedas a distant metastatic disease, and therefore it was sug-
gested to be treated with systemic therapy (either hormo-
nal or chemotherapy). Emerging data indicate, that rather
than a hematogeneous metastasis, the alteration of lymph-
atic drainage might have the pivotal role in the contralat-
eral axillary lymphatic metastases, to this area. In addition,
rarely native breast and axilla might have alternated
lymphatic drainage and should be determined. As many
studies show, contralateral axillary metastases and primary
breast cancer could be discovered either at the same time
or after having received treatment for recurring breast
cancer [21-24]. Although more data needs to be gathered,
a treatment approach for patients who have contralateral
axillary metastasis without distant metastases should be
curative in intent.
Therefore, synchronous or metachronous contralateral
axillary lymph nodes without systemic metastases could
be thought of as a curative disease due to the fact that
they are dispersalis lymphogenic and not hematogenous.
Despite a lack of consensus, patients seek this type of
treatment in the hope of being cured [23-28].
There is great optimism within the scientific literature
about the reliability of the capacity of re-operative SLNB
to determine whether or not there are axillary nodes that
test positive for metastasis [29-36]. Positive SLNs were dis-
covered in one out of seven (14.2%) patients of our series
(Table 1). After a mean 27-month follow-up period, no
local axillary recurrences have been found in any patients.
Conclusions
The present study draws attention to the increased prob-
ability of altered lymphatic drainage, resulting in new
nodes being found in sites other than the ipsilateral axilla
in patients who have had previous radiotherapy or previ-
ous operations. Because the altered lymphatic drainage
can be detected only by lymphoscintigraphy, we suggest a
lymphatic mapping injection followed by lymphoscintigra-
phy to identify the SLN in patients who have new or re-
current breast cancer and previous procedures (SLND or
ALND), rather than proceeding directly to an axillary dis-
section. It should be kept in mind that if ALND was done
or axillary radiotherapy carried out, it is highly unlikely
that the SLN will be found in the axilla. SLN mapping
with a radiocolloid is essential.
Our findings are consistent with prior studies that
imply re-operative SLNB is feasible, highly useful and
may provide a distinct advantage by creating an alterna-
tive to ALND for breast cancer patients (whether new
or reoccurring cancer) who have had a previous axillary
operation or SLNB [37,38]. A lymphoscintigraphy allows
identification of the sentinel nodes, whether or not they
pathologically involve cancer cells (represented by those
regional nodes with a negative predictive value of almost
definite), at their new unpredicted location. Further studies
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be required to determine fully the statistical significance of
operative lymphatic re-mapping.
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